HZNP News and Press, Horizon Therapeutics Public Limited Company From 07/01/22

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Arrowhead is a leader in RNAi. ARWR has a vast platform. I will wait for the first approval before investing. For further details see: Arrowhead Pharma: We Can Afford To Wait For More Proof

Joseph Papa resigned chairman position. Solta IPO cancellation discussed. BHC stock performance expectations. For further details see: Bausch Health Stock Soared By 20%: What To Do Now

-- Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the ...

Stocks that offer Growth at a Reasonable Price have had a rough Q2, lagging by one of their biggest margins even, Jefferies says. GARP is "defined by FY1 P/E divided by the long-term forecasted growth rate, strategist Steven DeSanctis wrote in a note. "We prefer the Q2 basket over the cheapes...

Horizon Therapeutics (NASDAQ:HZNP) on Wednesday said it had submitted a filing to Brazilian health regulator Anvisa for approval of its Uplizna medicine for the treatment of anti-aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder (NMOSD). NMOSD occurs when the bo...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency (ANVISA) for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis opti...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list , ranking No. 3 in the large company category. The list includes 15 top large sized companies, as well as 35 best small-to-medium workplaces in the ...

UBS has launched its coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Buy recommendation and as the firm’s top pick. Noting a clinical readout next year, the firm argues that the rare-disease-focused biotech is best positioned to accelerate growth through appealing business develo...